Hypertrophic cardiomyopathy & heart failure: exploring new options

Hypertrophic cardiomyopathy & heart failure: exploring new options

3 episodes
1.00 program credits
HCM HF exploring new options
  • Overview

    It is often forgotten that heart failure (HF) is a very important complication of hypertrophic cardiomyopathy (HCM). There are two pathways in HCM – an obstructive and non-obstructive pathway – that both may lead to HF. Three experts talk about risk factors of developing HF in patients with HCM, making the diagnosis and current and novel therapeutic agents for the management of these patients.

    This course consists of 3 episodes. Watch all episodes, answer pre- and post-test questions, and start earning CME credits.

  • Program Highlights

    This educational program consists of three presentations on HF and HCM.

    HCM and heart failure: is your patient at risk? - Rudolf de Boer, MD, PhD – Groningen, The Netherlands

    • How common is HF in HCM, should we care, and what are the risk factors? Rudolf de Boer provides answers to these questions.

    Recognizing HCM and HF: making the diagnosis - Mariana Brandão – Vila Nova de Gaia, Portugal

    • What are clinical presentations of HCM? By case presentations, Mariana Brandão shows different HCM phenotypes and the diagnostic tools to identify these.

    Managing patients with HCM and HF: what’s new in the therapeutic landscape? - Iacopo Olivotto, MD – Florence, Italy

    • HF in HCM occurs in two contexts: LV outflow obstruction during the early phase of HCM and disease progression at a later stage of HCM. Iacopo Olivotto talks about current and future therapeutic options in these two contexts.
  • Instructions

    • Watch the three lectures and answer the pre- and post-test questions
    • Fill in the evaluation questions
    • Download CME Certificate

    For questions regarding this activity, please contact us at info@pace-cme.org.

  • Learning Objectives

    • Distinguish between HCM and HCM complicated with heart failure with regard to prognosis
    • Recall the HCM phenotype with highest HF risk
    • Select the diagnostic tests for HCM
    • Memorize the mechanism of action of myosin inhibitors
    • Discuss the outcomes of phase 3 trials with myosin inhibitors in patients with obstructive HCM
  • Target Audience

    This educational activity is designed for all healthcare professionals with an interest in management of patients with HCM.

  • Accreditation and Credit Designation Statements

    This online course is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit.

    Through an agreement between EBAC and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

  • Commercial Support

    Funding for this educational program was provided by an unrestricted educational grant from Bristol Myers Squibb.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of PACE-cme.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free